Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Cancer Networks" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Cancer Networks for you to read. Along with our medical data and news we also list Cancer Networks Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cancer Networks Companies for you to search.
Salvage prostate therapy following local recurrence post radiation may be a safe way to avoid or delay initiation of hormone deprivation.
The approval is tremendous news and should have a profound impact on patients with the rare tumor, according to experts.
A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.
A new analysis of PROSPER, presented at AUA 2018, suggests enzalutamide plus ADT may be superior to ADT alone in nonmetastatic CRPC.
MSKCC’s Dr. Nancy Kemeny discusses the impact of a company's decision to halt manufacture of a pump used to treat liver mets from colon and rectal cancers.
Cancer patients get inundated with advice, how much of it can be trusted?
The presence and burden of single nucleotide variants as measured in cell-free DNA may have substantial prognostic utility in patients with melanoma who have metastases.
Researchers have developed a “disease screening pill” that could allow for a noninvasive and safe method for detecting breast cancer using only near-infrared light.
After non-oncology units received comprehensive safety kits for handling oral hazardous drugs, chemo handling precautions at Maine Medical Center increased significantly.
Detailed education and other initiatives related to CHG cloth use boosted bathing compliance rates by 95% in 14 months, and decreased CLABSI by 8%.
A study led by Dr. Jun Mao of MSKCC found CBT and acupuncture each yielded clinically meaningful and durable sleep-related QOL improvements.
Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.
Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial.
A Moffitt team suggests mathematical modeling may guide the optimal cancer treatment dosing approach better than MTD.
While HCT is an important benefit for FL patients, the optimal approach remains up for debate.
TPIV200 stimulates T cells to attack ovarian and triple negative breast tumor cells that over-express the folate receptor alpha protein.
Recurrence risk was greater in sarcopenic patients, and greater alpha-fetoprotein and microvascular invasion were independent risk factors.
In this podcast, Kelly Brassil, PhD, RN, discusses irAEs and ONS’s role in developing an ASCO/NCCN guideline for their management.
In this podcast, Kelly Brassil, PhD, RN, discusses irAEs and ONS’s role in developing ASCO/NCCN guidelines for their management.
A streamlined nursing protocol reduced delays related to treatment with oral formulations of chemotherapy and immunotherapy, and increased patient satisfaction.
In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.
In this Q&A, we discuss the research into the relationships between gut microbiota, diet, and colorectal cancer.
A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.
Here, we discuss how to improve adherence to endocrine therapy in women with HR-positive breast cancer, as well as the side effects and the reasons for discontinuation.
In this review, we highlight prospective data on checkpoint inhibition alone and in combination, discuss data regarding the efficacy and toxicity of combination therapy, and identify clinical scenarios that may favor treatment with combination therapy.